Leerink Partnrs Issues Optimistic Outlook for JANX Earnings

Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) - Equities researchers at Leerink Partnrs lifted their Q2 2025 earnings per share (EPS) estimates for Janux Therapeutics in a note issued to investors on Monday, May 12th. Leerink Partnrs analyst J. La. Rosa now forecasts that the company will earn ($0.47) per share for the quarter, up from their prior estimate of ($0.49). The consensus estimate for Janux Therapeutics' current full-year earnings is ($1.38) per share. Leerink Partnrs also issued estimates for Janux Therapeutics' Q3 2025 earnings at ($0.54) EPS, Q4 2025 earnings at ($1.04) EPS, FY2025 earnings at ($2.43) EPS, FY2026 earnings at ($4.76) EPS, FY2027 earnings at ($5.42) EPS, FY2028 earnings at ($4.20) EPS and FY2029 earnings at ($2.01) EPS.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.38) EPS for the quarter, beating analysts' consensus estimates of ($0.43) by $0.05. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%.

JANX has been the topic of a number of other reports. Scotiabank decreased their price objective on Janux Therapeutics from $62.00 to $41.00 and set a "sector perform" rating on the stock in a report on Friday, February 28th. Wedbush reissued an "outperform" rating and issued a $76.00 target price (up previously from $75.00) on shares of Janux Therapeutics in a research report on Friday, February 28th. Finally, HC Wainwright reissued a "buy" rating and issued a $70.00 target price on shares of Janux Therapeutics in a research report on Monday, March 3rd. One research analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $95.25.

Janux Therapeutics Stock Performance

JANX opened at $25.33 on Wednesday. Janux Therapeutics has a one year low of $22.52 and a one year high of $71.71. The stock has a market capitalization of $1.50 billion, a PE ratio of -21.65 and a beta of 3.24. The business's 50 day moving average price is $29.06 and its 200 day moving average price is $41.29.

Insider Transactions at Janux Therapeutics

In related news, Director Ra Capital Management, L.P. acquired 341,742 shares of the business's stock in a transaction dated Wednesday, March 5th. The shares were acquired at an average price of $30.64 per share, with a total value of $10,470,974.88. Following the completion of the transaction, the director now owns 9,658,988 shares of the company's stock, valued at $295,951,392.32. The trade was a 3.67% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Andrew Hollman Meyer sold 3,334 shares of the stock in a transaction on Monday, April 21st. The shares were sold at an average price of $30.00, for a total value of $100,020.00. Following the completion of the transaction, the insider now directly owns 82,139 shares in the company, valued at $2,464,170. This trade represents a 3.90% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 10,001 shares of company stock valued at $313,964. 8.10% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Janux Therapeutics

Several large investors have recently bought and sold shares of the business. Aberdeen Group plc grew its holdings in shares of Janux Therapeutics by 250.8% during the first quarter. Aberdeen Group plc now owns 224,788 shares of the company's stock worth $6,069,000 after purchasing an additional 160,716 shares during the last quarter. E Fund Management Co. Ltd. grew its holdings in shares of Janux Therapeutics by 6.3% during the first quarter. E Fund Management Co. Ltd. now owns 68,644 shares of the company's stock worth $1,853,000 after purchasing an additional 4,076 shares during the last quarter. Russell Investments Group Ltd. grew its holdings in shares of Janux Therapeutics by 15,117.4% during the first quarter. Russell Investments Group Ltd. now owns 153,848 shares of the company's stock worth $4,154,000 after purchasing an additional 152,837 shares during the last quarter. Nuveen LLC purchased a new position in shares of Janux Therapeutics during the first quarter worth about $3,339,000. Finally, Deutsche Bank AG grew its holdings in shares of Janux Therapeutics by 7.2% during the first quarter. Deutsche Bank AG now owns 99,691 shares of the company's stock worth $2,692,000 after purchasing an additional 6,662 shares during the last quarter. Hedge funds and other institutional investors own 75.39% of the company's stock.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.